[go: up one dir, main page]

GB202401381D0 - Anti-actin antibodies - Google Patents

Anti-actin antibodies

Info

Publication number
GB202401381D0
GB202401381D0 GBGB2401381.5A GB202401381A GB202401381D0 GB 202401381 D0 GB202401381 D0 GB 202401381D0 GB 202401381 A GB202401381 A GB 202401381A GB 202401381 D0 GB202401381 D0 GB 202401381D0
Authority
GB
United Kingdom
Prior art keywords
actin antibodies
actin
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2401381.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Francis Crick Institute Ltd
Original Assignee
Francis Crick Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francis Crick Institute Ltd filed Critical Francis Crick Institute Ltd
Priority to GBGB2401381.5A priority Critical patent/GB202401381D0/en
Publication of GB202401381D0 publication Critical patent/GB202401381D0/en
Priority to PCT/EP2025/052709 priority patent/WO2025163203A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
GBGB2401381.5A 2024-02-02 2024-02-02 Anti-actin antibodies Ceased GB202401381D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2401381.5A GB202401381D0 (en) 2024-02-02 2024-02-02 Anti-actin antibodies
PCT/EP2025/052709 WO2025163203A1 (en) 2024-02-02 2025-02-03 Anti-f-actin antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2401381.5A GB202401381D0 (en) 2024-02-02 2024-02-02 Anti-actin antibodies

Publications (1)

Publication Number Publication Date
GB202401381D0 true GB202401381D0 (en) 2024-03-20

Family

ID=90236316

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2401381.5A Ceased GB202401381D0 (en) 2024-02-02 2024-02-02 Anti-actin antibodies

Country Status (2)

Country Link
GB (1) GB202401381D0 (en)
WO (1) WO2025163203A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
US20170307609A1 (en) * 2014-10-01 2017-10-26 Henry Ford Health System Methods for Treating Sepsis and Biomarkers Related Thereto
EP4284835A4 (en) 2021-01-29 2025-05-28 Chugai Seiyaku Kabushiki Kaisha MOLECULE WITH SPECIFIC EFFECT IN A TISSUE WITH OBSERVATION OF CELL DEATH
WO2024018062A1 (en) * 2022-07-21 2024-01-25 The Francis Crick Institute Limited Immunoconjugate
WO2024024882A1 (en) * 2022-07-28 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Molecule specifically acting in a tissue where a cell death being observed

Also Published As

Publication number Publication date
WO2025163203A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
GB202305426D0 (en) Antibodies
GB202401381D0 (en) Anti-actin antibodies
GB202304512D0 (en) Antibodies
GB202217924D0 (en) Antibodies
GB202204159D0 (en) Antibodies
GB202507044D0 (en) Antibodies
GB202416214D0 (en) Antibodies
GB202416216D0 (en) Antibodies
GB202413525D0 (en) Antibodies
GB202411940D0 (en) Anti-CLEC12A Antibodies
GB202410983D0 (en) Antibodies
GB202410982D0 (en) Antibodies
GB202409026D0 (en) Antibodies
GB202405480D0 (en) Antibodies
GB202404344D0 (en) Antibodies
GB202404343D0 (en) Antibodies
GB202400941D0 (en) Antibodies
GB202504529D0 (en) Antibody
GB202417731D0 (en) ZIP12 Antibody
GB202408492D0 (en) Anti-alpha-synuclein antibody
GB202319255D0 (en) Anti-UNC5C antibodies
GB202318820D0 (en) Antibodies
GB202317371D0 (en) Anti-unc5c antibodies
GB202317189D0 (en) Anti-AGR2 antibodies
GB202317192D0 (en) Anti-agr2 antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)